8-K: NextCure Prioritizes Cancer Programs, Announces Restructuring and Extends Cash Runway into 2026

NextCure is focusing on its NC410 and LNCB74 programs, restructuring operations, and extending its cash runway into the second half of 2026.

Summary

• NextCure has announced a strategic shift to prioritize two key programs: NC410, a LAIR-2 fusion protein, and LNCB74, a B7-H4 antibody-drug conjugate (ADC).
• The company is restructuring its operations, including a 37% workforce reduction, to better align resources with these prioritized programs.
• This restructuring is expected to result in one-time charges of approximately $0.8 million, primarily for severance and benefits.
• NextCure's cash position of approximately $108 million, combined with the restructuring, is now expected to fund operations into the second half of 2026.
• Clinical data for NC410 in combination with pembrolizumab shows a 42.8% overall response rate (ORR) and 42.8% disease control rate (DCR) in ovarian cancer patients, with 3 partial responses out of 7 evaluable patients.
• In colorectal cancer, NC410 combo shows a 10.5% ORR and 47.3% DCR in 19 evaluable patients, with a median progression-free survival (mPFS) of 8.1 months.
• LNCB74, developed in collaboration with LegoChem Biosciences, is planned for an Investigational New Drug (IND) filing by the end of 2024.
• The company intends to seek partners for its other assets, including NC525, NC605, and NC181.
• Research and development expenses for 2023 were $47.9 million, down from $54.2 million in 2022.
• The net loss for 2023 was $62.7 million, compared to $74.7 million in 2022.

Sentiment

Score: 7

Explanation: The document presents a positive strategic shift with promising clinical data and an extended cash runway, but the restructuring and workforce reduction temper the overall sentiment. The company is clearly focusing on its core assets and has a clear plan to advance them.

Positives

• The prioritization of NC410 and LNCB74 focuses resources on promising clinical programs.
• The restructuring extends the cash runway into the second half of 2026, providing financial stability.
• Early clinical data for NC410 combo shows promising response rates in both ovarian and colorectal cancers.
• The collaboration with LegoChem Biosciences for LNCB74 leverages expertise in ADC development.
• The company has a differentiated approach to ADC development with LNCB74, including a unique linker technology.
• The company has a clear plan to advance its two lead programs through important near-term clinical milestones.
• The company has a strong understanding of the biology of the extracellular matrix and its role in tumor resistance.
• The company has a validated patient selection assay for B7-H4.

Negatives

• The restructuring includes a 37% workforce reduction, which may impact morale and operations.
• The company is seeking partners for other assets, indicating a lack of internal resources to advance them independently.
• The company has a history of significant losses.
• The company is dependent on key personnel.
• The company has no products approved for commercial sale.

Risks

• Clinical trial results may not be predictive of future outcomes.
• The company may need to obtain additional financing.
• There are risks related to clinical development, marketing approval, and commercialization.
• The company is dependent on key personnel.
• The company has a limited operating history.
• The company's approach to drug discovery is unproven.
• The company is subject to the impacts of the COVID-19 pandemic.

Future Outlook

NextCure expects its existing cash, cash equivalents, and marketable securities will enable it to fund operating expenses and capital expenditures into the second half of 2026. The company plans to advance its two lead programs, NC410 and LNCB74, through important near-term clinical milestones and seek partners for its other assets.

Management Comments

• Michael Richman, NextCure's president and chief executive officer, stated that clinical data generated in 2023 enabled the company to objectively assess each program and set priorities for 2024.
• Mr. Richman also mentioned that the company is excited to focus on NC410 combo, which is demonstrating clinical responses in ovarian and colorectal cancers.
• Mr. Richman noted that the company believes it can advance its two programs through important near-term clinical milestones given its current cash position and revised runway to the second half of 2026.

Industry Context

The focus on antibody-drug conjugates (ADCs) and immuno-oncology aligns with current trends in the biopharmaceutical industry. The collaboration with LegoChem Biosciences highlights the increasing importance of partnerships in ADC development. The prioritization of specific programs and restructuring reflects a broader trend of companies focusing on core assets to maximize efficiency and extend cash runways.

Comparison to Industry Standards

• The reported overall response rate (ORR) of 42.8% for NC410 in ovarian cancer is promising compared to standard treatments for relapsed/refractory ovarian cancer, where ORRs are often in the 10-20% range.
• The 10.5% ORR for NC410 in colorectal cancer is modest, but the 47.3% disease control rate and 8.1 month median progression-free survival suggest potential benefit in a difficult-to-treat population.
• The development of LNCB74 as a B7-H4 ADC puts NextCure in competition with companies like GSK, which recently acquired a B7-H4 asset for $1.4 billion, indicating the high value placed on this target.
• The use of a glucuronidase cleavable linker in LNCB74 is a differentiated approach compared to other ADCs that use val-cit linkers, potentially offering improved safety and efficacy.
• The company's focus on the tumor microenvironment and extracellular matrix is a novel approach compared to traditional immuno-oncology strategies.

Stakeholder Impact

• Shareholders may view the prioritization of key programs and extended cash runway positively.
• Employees impacted by the workforce reduction will experience job loss.
• Patients with ovarian and colorectal cancer may benefit from the development of NC410.
• Patients with other cancers may benefit from the development of LNCB74.
• Potential partners may be interested in the company's other assets.

Next Steps

• Enroll additional patients in the NC410 ovarian and colorectal cancer cohorts.
• Present data from the ovarian cancer patients in the second half of 2024.
• Present data from the colorectal cancer patients in the second quarter of 2024.
• Submit an IND application for LNCB74 by the end of 2024.
• Complete the dose-finding portion of the NC525 trial by the fourth quarter of 2024.
• Continue toxicology studies for NC605.
• Seek partners for NC525, NC605, and NC181.

Key Dates

Keywords

NC410, LNCB74, antibody-drug conjugate, ADC, cancer, ovarian cancer, colorectal cancer, restructuring, clinical trials, biopharmaceutical, LAIR-2, B7-H4, immunotherapy, extracellular matrix, LegoChem Biosciences